Physician profile
James Patrick Satteson
NPI 1669146882
$3,499.88
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $834 · 2024: $1,146 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.67 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $675.63 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $643.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $445.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $374.19 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $308.75 | 2022-2025 | Bexsero, Trelegy Ellipta, Arexvy |
| Amgen INC. | $146.72 | 2023-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.64 | 2022-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $104.63 | 2022-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $86.88 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $76.64 | 2023-2025 | |
| Dexcom, INC. | $69.15 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $66.43 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $59.41 | 2022-2023 | Eliquis |
| Exact Sciences Corporation | $56.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $54.09 | 2025 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.50 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $25.04 | 2022 | |
| Neurelis, INC. | $18.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.36 | 2024 | Xifaxan |
| Corcept Therapeutics | $16.49 | 2025 | Korlym |
| Cequr Corporation | $15.97 | 2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $14.94 | 2022 | |
| Inspire Medical Systems, INC. | $14.86 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Satteson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.